Phase 2 N=137 Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Lupus Nephritis · Lupus Erythematosus, Systemic
Primary: Number of Participants With Complete Response — 22; 21 participants — p=0.85
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Hyperphosphatemia · End-stage Renal Disease
Primary: The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28) — 5.9; 5.4 mg/dL
Phase 2 N=39 Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer
Prostate Cancer
Primary: Maximum Tolerated Dose and Toxicity Profile
Phase 2 N=1,361 A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females
Bone Mineral Density
Primary: Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD) — 2.26; 1.45; 2.50 percent change
Phase 2 N=40 Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Crohn's Disease
Primary: • Evaluate the Effectiveness of the PillCam COLON 2 Bowel Prep Regimen in Crohn's Disease Patients — 62; 79 percentage of participants
Phase 2 N=71 A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)
Rhinitis, Allergic, Perennial and Seasonal
Primary: Weighted Mean of the Total Nasal Symptom Score (TNSS) (0-4) Hours (h) Post Start of Allergen Chamber Challenge on Day 8 of Each Treatment Period — 6.030; 4.189; 4.500…
Phase 2 N=168 A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
Stomach Cancer · Esophageal Cancer
Primary: Progression-Free Survival (PFS) — 6.4; 6.7 months — p=0.886
Phase 2 N=55 Fall Prevention Program for Older Adults
Accidental Falls
Primary: Number of Participants Who Fell on a Tripping Test — 2; 4 participants — p=0.45
Phase 2 N=14 Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
Adult Synovial Sarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants
Phase 2 N=59 Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)
HIV Infections · Episodic Substance Use
Primary: Total Unprotected Anal Intercourse Events (Exclusive of Those Events With a Primary HIV-negative Partner) — 4.23; 3.91; 3.41; 2.05 Self reported events in past 3 months
Phase 2 N=124 A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme
Primary: Overall Survival (OS) — 18.3; 16.7 months of survival
Phase 2 N=147 Market Potential of Carbon Dioxide Nasal Spray
Nasal Congestion
Primary: Which One Product That Relieves Nasal Congestion do You Buy Most Often? — 46; 29; 6; 3 Participants
Phase 2 N=52 A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Nonsquamous Non-Small Cell Neoplasm of Lung · Non-Small Cell Lung Cancer Metastatic · Non-Small Cell Lung Cancer Stage IIIB
Primary: Percentage of Participants Who Adhered to Treatment Administration at Home — 100; 98.0; 98.0; 98.0 percentage of participants
Phase 2 N=64 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Adult Anaplastic Oligodendroglioma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…
Phase 2 N=64 Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
HER2 Positive Breast Carcinoma · Recurrent Breast Carcinoma · Stage IIIB Breast Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.0; 4.9 Median survival and CI in months — p=.89